ORAL

Allogenic mesenchymal stem cell transplantation for chronic obstructive pulmonary disease

Le Thi-Bich Phuong

Van Hanh Stem Cell Unit, Van Hanh General Hospital, Ho Chi Minh City, Vietnam

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is the chronic condition in which there is progressive obstruction of air flow in and out of the lungs. COPD is characterized by inflammation and its intensification with the participation of immune cells. Currently, there is no effective treatment and the goal of COPD treatment is relieve the symptoms and improve quality of life. The prevalence and mortality rate increase rapidly annual leads COPD to the third leading cause of death worldwide.

Stem cell based therapy offers a promising approach to COPD. The main mechanism of stem cell based therapy is capacity of immunomodulation, bacterial clearance, hypertension pulmonary pressure reversal and others.

Method: We conduct the clinical trial using allogenic umbilical cord mesenchymal stem cell in 10 patients with COPD stage C and D. Route of administration is intravenously infusion. Dose of infusion is 1.5 x 10^6 cells/kg of weight. We follow the safety and efficacy during 6 months by index od SAEs, the number of COPD attacks, CAT, mMRC score, 6minute walking test, hsCRP and Spirometry.

Result: The improvement of patient’s condition happens after 1 month after stem cell infusion. The amelioration lasts up to 6 month follow up which expressed by clinical index, FEV1 and hsCRP. Besides, there is no serious adverse effects happens.

Conclusion: Allogenic umbilical cord mesenchymal stem cell is proven to be safe in COPD patients. Our trial shows the initial efficacy in COPD treatment. We need more strong evidence to support this approach.

Keywords

Funding

References